Wait a second!
More handpicked essays just for you.
More handpicked essays just for you.
Why do monopolies benefit the pharmaceutical industry
Competition in the pharmaceutical market
Business aspects of the pharmaceutical industry
Don’t take our word for it - see why 10 million students trust us with their essay needs.
Why do consumers purchase specific drugs for various ailments, sicknesses or diseases they might have? Why do physicians prescribe certain drugs over competitive drugs that may be available to the public? Why is it that most of us can easily name specific drugs that fit the many ailments of today’s society? On the surface the answer might be as simple as good TV advertising or radio commercials or even internet adds. The truth of matter is the major pharmaceutical manufacturers own the patents on these drugs and this gives them all of the marketing budget and muscle they need to promote the drug and control the pricing. The incentives for larger pharmaceutical companies are very enticing and as a result, they don’t mind spending the time in clinical trials and patent courts to get their drugs approved. Some will even get patents on the process by which the drug is manufactured, ensuring that no competitor can steal the drug or the process. This protects their large financial investment and nearly guarantees a large return for their investors. Many consumer rights groups claim this is nothing more than legalizing monopolies for the biggest manufacturers. A monopoly exists when a specific individual or an enterprise has sufficient control over a particular product or service to determine significantly the terms on which other individuals shall have access to it. A monopoly sells a good for which there is no close substitute. The absence of substitutes makes the demand for the good relatively inelastic thereby enabling monopolies to extract positive profits. It is this monopolizing of drug and process patents that has consumer advocates up in arms. The granting of exclusive rights to pharmacuetical companies over clinical a... ... middle of paper ... ... also in future research. Works Cited Friedman, Milton. 2002. Capitalism and Freedom. Pages 127-128. Lehman, Bruce. 2003. “The Pharmaceutical Industry and the Patent System”. International Intellectual Property Institute. Pages 1-14. Yu, Winnie and Joel Hay. 1999. “Drug Patents and Prices: Can we Achieve Better Outcomes?” Measuring the Prices of Medical Treatments. Pages 27-28. Food and Drug Administration. 2004. “Savings from Generic Drugs Purchased at Retail Pharmacies”, http://web.archive.org/web/20080223131005/http://www.fda.gov/cder/consumerinfo/savingsfromgenericdrugs.htm. Meurer, Michael. “Pharmacogenomics, Genetic Tests, and Patent-Based Incentives”, Boston University School of Law. Pages 1-8. Grabowski, Henry and John Vernon. 1986. “Longer Patents For Lower Imitation Barriers: The 1984 Drug Act”, The American Economic Review. Pages 196-198.
(7) Hall B. Patents and Patent Policy -. 2007. The 'Secondary' of the 'Secondary' of the 'Secondary' of the 'Secondary' of the 'Secondary' of the 'Secondary' of the 'Secondary' of the Morse H. SETTLEMENT OF INTELLECTUAL PROPERTY DISPUTES IN THE PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRIES: ANTITRUST RULES. Allison JR, Lemley MA, Moore KA, Trunkey RD. Valuable patents. Geol.
In Melody Peterson’s “Our Daily Meds” , the history of marketing and advertising in the pharmaceutical industry is explored. The first chapter of the book, entitled “Creating disease”, focuses on how major pharmaceutical companies successfully create new ailments that members of the public believe exist. According to Peterson, the success that these drug manufacturers have experienced can be attributed to the malleability of disease, the use of influencial people to promote new drugs, the marketing behind pills, and the use of media outlets.
Federal Trade Commission, 1979. Braithwalte, John. The. Corporate Crime in the Pharmaceutical Industry? Boston, MS: Routledge & Kegan Paul, 1984.
“Pure Food and Drug Act 1906.” 34 U.S. Stats. 768, quoted in Medicine in the Americas, Bethesda, Maryland: National Library of Medicine, 2004. http://www.ncbi.nlm.nih.gov/books/NBK22116/.
3Walker, Hugh: Market Power and Price levels in the Ethical Drug Industry; Indiana University Press, 1971, P 25.
Although monopolies appear damaging at times, there are arguments that they are an advantage to society. Monopolies in the pharmaceutical industry drive companies to pursue research and development (R&D) efforts to gain new patents. According to a 1992 study, among the 24 US. Industry groups, pharmaceuticals dedicated 16.6% of their amounts to basic research, while all other industries averaged at 5.3% (Sherer 1307). This fact validates the incentive pharmaceutical companies have to get a patent and acquire more power. Pfizer encourages R&D because of the incentives and a want to obtain patents to receive more profit. Pfizer has to promote itself to be successful, creating a good brand image that consumers will trust. If the company can advertise successfully, more consumers will purc...
In recent years’ health reform has been a driving force in the United States political system. If you watch the news you will undoughtabley hear how citizens, the government, or the economy is or might be effected by some sort of change in medical regulation. One of these hot topic issues is the cost of prescription drugs. Every major drug market besides the United States regulates the price of drugs in some way (Abbott and Vernon). By the United states not doing so many believes it opens consumers up to be exploited by large pharmaceuticals companies. Other believe regulating drug prices limits investment, innovation, and competition in the pharmaceutical industry. In many ways both views are correct yet the later may have more long term lasting
Pharmaceutical patents are patents for inventions within the pharmaceutical industry. Patents give exclusive rights for an invention for a product or a process of making a product [1]. There are many aspects to patents in the pharmaceutical industry that are both pros and cons; it just depends on what industry you are in. Pharmaceutical companies take out patents so they can regulate the market and restrict competition from other companies. By obtaining patents pharmaceutical companies also attract investment. In addition to this pharmaceutical companies can also regulate the price of the drug as they will be the only company selling that drug. However these aspects of patents can adversely affect the generics industry. The generics industry cannot make or sell drugs that are patented but once a patent licence expires, both the generics industry and the WHO see increased benefits as drugs become more widely available around the world (i.e. developing countries) at a lower price. Here we will discuss the pros and cons of patents from the point of view of the pharmaceutical industry, generics industry and the WHO.
This week’s case study concerning Genzyme’s strategic direction was very interesting in that they essentially pursued a strategy that seemingly was purposely avoided by other players in the pharmaceutical industry (Schilling, N.D.). Their strategy centered on developing prescriptions for rare diseases. Typically “developing a drug takes 10 to 14 years and costs an average of $800 million to perform the research, run the clinical trials, get FDA approval, and bring a drug to market,” and in turn it is normally intuitive, from an economic standpoint, to attempt to develop drugs that will have a substantial market so to be able to assure enough revenue is generated to produce a significant profit. In turn, drugs marketed towards treating
One thing is guaranteed to happen; people will always get sick. Diseases and bacteria are always changing and the human body’s immune system isn’t always prepared to fight it off. The pharmaceutical industry knows this, and that’s why they are a multi-billion dollar industry. Today, you will see a pill that will virtually cure every kind of “disease” out there whether it’s physical, emotional, or neurological. What is a “disease”? Supposedly if you have constant headaches, you have a disease. If you’re overweight, you have a disease. If you have trouble concentrating, you have a disease. Any little problem that you can think of, there most likely will be a pill out there that will “cure” that problem. First, your body is the only thing that can cure a disease. Second, everyone experiences these little problems and there are simple solutions that can “cure” these problems without the expensive pills that can cause harmful side effects. Why isn’t this information being told to us? Because of money. Notice that in all commercial breaks there is a commercial advertising some kind of pill for a certain kind of problem. They make so much money that the drug companies can employ thousands of lobbyists to bribe, lie, and payout almost anyone they need to to get them to advertise their product. Even politicians benefit from the pharmaceutical companies, and if politicians have their back, then how can they be expected to be stopped? Modern medicine has no doubt done wonders for many people to get better from illnesses, but this industry is getting way out of hand.
Monopolies are when there is only one provider of a specific good, which has no alternatives. Monopolies can be either natural or artificial. Some of the natural monopolies a town will see are business such as utilities or for cities like Clarksville with only one, hospitals. With only one hospital and there not being another one for a two hour drive, Clarksville’s hospital has a monopoly on emergency care, because there is not another option for this type of service in the area. Artificial monopolies are created using a variety of means from allowing others to enter the market. Artificial monopolies are generally rare or absent because of anti-trust laws that were designed to prevent this in legitimate businesses. However, while these two are the ends of the spectrum, the majority of businesses wil...
This Dissertation, titled “Impact of TRIPS on Indian patent regime with reference to pharmaceutical sector” has been written and based on doctrinal method of research which involves the collection of data from secondary sources, like books written by authors and articles found in journals and websites. No empirical research methodology is employed in this work. Library sources and Internet has provided with a major contribution of most relevant and latest information on the web, which helped to explore the subject through various dimensions. NALSAR University of Law, Hyderabad and library’s e- resources like Westlaw, Hein online have played a crucial role for the researcher to bring out materials for dissertation. Throughout this paper researcher has followed a uniform mode of citation.
product differntiation :- This is the most distinct feature of monopolistic competation. In this market, all the producers are selling similar, but not the same products. The Shampoo are available under different brand name, colours, size, smell. Packing etc. For eg, clinic plus, Dove, Head & shoulders, Sunnsilk, L’Oreal etc. Product differentiation gives rise to an element of monopoly to each producer under monopolistic competation. Thus according to Chamberlin,monopolistic competation. is a blend of monopoly and perfect competition.for eg, I like only Dove because of its special colour, smell or its name. Any other shampoo cannot substitute Dove for me. It is clear that products in monopolistic competation, are not same as in Perfect Competition, neither are they are remote substitutes as monopoly. Real qualitative differences between the products may not be very strong in this market, but imaginary differences through packing, brand name, colour, are more strong in this
According to Express Script’s Prescription Price Index, just last year, the prices of brand-name drugs have increased by an average of 16.2%. The pharmaceutical companies are able to do this because of two main reasons: 1) they spend more money lobbying than any other industry, 2) The Food and Drug Administration’s patent approval processes. In 2015, the Pharmaceutical Research and Manufacturers of America, the primary pharmaceutical lobbying organization, spent more than $230 million on lobbying politicians. This creates an obstacle for change as politicians influenced by these large drug companies vote for legislation that favor them. For example, the pharmaceutical industry has spent $70 million already this year, trying to fight a California initiative that would give states the right to negotiate prices, as well as get legal binding discounts on drugs that are patent protected (Time).
A monopoly is “a single firm in control of both industry output and price” (Review of Market Structure, n.d.). It has a high entry and exit barrier and a perceived heterogeneous product. The firm is the sole provider of the product, substitutes for the product are limited, and high barriers are used to dissuade competitors and leads to a single firm being able to ...